Gaboxadol

Gaboxadol
Trade Name
Orphan Indication Fragile X syndrome
USA Market Approval USA
USA Designation Date 2017-10-03 00:00:00
Sponsor Ovid Therapeutics;1460 Broadway;New York, New York, 10036